PBYI (Puma Biotechnology Inc) צמיחת רווח נקי למניה השנה

Puma Biotechnology (PBYI) is betting on the monetization of its sole approved drug while avoiding mergers. The GURU.Markets terminal provides a chart of annual earnings per share growth, where the latest value is recorded as 0.00. The company generates revenue from supplying Nerlynx to the B2B oncology segment, however, a high debt load and the risk of generic entry following patent expiration limit its investment attractiveness.

This indicator calculates the year-over-year dynamics of net earnings per share, reflecting the efficiency of capital generation relative to previous periods. By analyzing the annual EPS growth profile, an investor can see the dependence of Puma Biotechnology (PBYI) revenues on the commercialization of a single oncology drug, which allows for an assessment of the risks associated with a lack of portfolio diversification through the lens of this metric's volatility.